Risk Factors and Outcomes of Recurrent Cytomegalovirus Infection in Heart Transplant Recipients
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70342 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Transplantation, 2025. Verfasst von Vaisak O Nair und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Section of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Heart Transplantation, Transplant Recipients, Graft Rejection. Die Arbeit nennt 34 Literaturangaben. Gefördert von: National Center for Advancing Translational Sciences (NCATS).
Abstract (Originalsprache)
Purpose
The purpose of this study was to evaluate the incidence and risk factors for developing recurrent clinically significant cytomegalovirus infections (csCMVi) in heart transplant recipients.
Methods
We conducted a retrospective cohort study involving adult heart transplant recipients at three large transplant centers in the United States between January 2011 and March 2019. All patients with a history of csCMVi, defined as CMV disease or CMV infection requiring preemptive therapy, were followed from the date of treatment completion for the primary csCMVi episode. Outcomes of interest were recurrent csCMVi and all‐cause mortality.
Results
Among 98 heart transplant recipients with csCMVi, 22 (22.4%) episodes of recurrent csCMVi occurred. Median time‐to‐recurrent csCMVi was 31.5 (IQR 21.3–59.8) days following treatment completion. A preceding episode of CMV disease (versus infection) was associated with a lower risk of recurrent csCMVi (HR 0.29, 95% CI 0.08–0.98; p = 0.047). Patients with lymphopenia had higher rates of recurrent csCMVi without statistical significance (HR 2.13, 95% CI 0.88–5.13; p = 0.093). Seroconversion by the end‐of‐therapy among CMV D+/R− mismatched patients was associated with a reduced risk of csCMVi recurrence (HR 0.07, 95% CI 0.02–0.30; p < 0.001). Overall, 17 (17.3%) patients died during follow‐up, which was not significantly higher among those with recurrent csCMVi (HR 2.13, 95% CI 0.78–5.79; p = 0.141).
Conclusions
About one in five heart recipients with csCMVi developed post‐treatment recurrence. A preceding episode of CMV disease and seroconversion was protective against recurrence. Lymphopenia may be a practical biomarker to stratify recurrence risk. Overall, recurrent csCMVi was not significantly associated with mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Section of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Infectious Disease, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
- Department of Infectious Diseases, Mayo Clinic, Jacksonville, Florida, USA.
- Division of Infectious Diseases and Transplant Center, Mayo Clinic, Phoenix, Arizona, USA.
ORCID-Profile: Vaisak O Nair, Zachary A Yetmar, Bismarck S Bisono-Garcia, Lisa Brumble, Holenarasipur R Vikram, Raymund R Razonable, Elena Beam
Förderung
- National Center for Advancing Translational Sciences (NCATS)
Zitieren
APA
Nair, V. O., Yetmar, Z. A., Bisono-Garcia, B. S., Brumble, L., Vikram, H. R., Razonable, R. R., & Beam, E. (2025). Risk Factors and Outcomes of Recurrent Cytomegalovirus Infection in Heart Transplant Recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.70342
Vancouver
Nair VO, Yetmar ZA, Bisono-Garcia BS, Brumble L, Vikram HR, Razonable RR, et al. Risk Factors and Outcomes of Recurrent Cytomegalovirus Infection in Heart Transplant Recipients. Clinical Transplantation. 2025. doi:10.1111/ctr.70342
BibTeX
@article{Nair2025,
author = {Nair, Vaisak O and Yetmar, Zachary A and Bisono-Garcia, Bismarck S and Brumble, Lisa and Vikram, Holenarasipur R and Razonable, Raymund R and Beam, Elena},
title = {Risk Factors and Outcomes of Recurrent Cytomegalovirus Infection in Heart Transplant Recipients},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70342}
}
EUVIMED